RxDoctor Payments Data

Jose Ugarte, MD

Family Medicine · Kingsville, TXNPI 1457333882

Payments from drug & device makers

$982in general payments, 2019–2025

Across 33 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$427
  • AstraZeneca$215
  • Amarin Pharma, Inc.$159
  • Novartis$107
  • Amgen$37
  • Abbott$23
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC10$427
AstraZeneca8$215
Amarin Pharma, Inc.4$159
Novartis6$107
Amgen3$37
Abbott1$23
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,974
Medicare patients
90
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide244$281,689
FarxigaDapagliflozin Propanediol347$223,153
OzempicSemaglutide92$95,745
EliquisApixaban69$35,367
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$25,487
XareltoRivaroxaban34$23,459
VascepaIcosapent Ethyl85$21,862
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog55$21,442
JardianceEmpagliflozin24$20,575
JanuviaSitagliptin Phosphate69$19,592
EntrestoSacubitril/Valsartan44$19,544
TrulicityDulaglutide18$15,381
MyrbetriqMirabegron52$15,121
DapagliflozinDapagliflozin Propanediol35$14,411
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$427$297,070262 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$215$264,983429 claims
MerckJanuvia$13$19,59269 claims
NovartisEntresto$107$19,54444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Kingsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →